cimetidine in sodium chloride- Cimetidine and Sodium Chloride injection, solution United States - English - NLM (National Library of Medicine)

cimetidine in sodium chloride- cimetidine and sodium chloride injection, solution

hospira, inc. - cimetidine (unii: 80061l1wgd) (cimetidine - unii:80061l1wgd) - injection, solution - 6 mg in 1 ml - cimetidine hydrochloride injection is indicated in: (1) short-term treatment of active duodenal ulcer. most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see dosage and administration − duodenal ulcer). concomitant antacids should be given as needed for relief of pain. however, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) short-term treatment of active benign gastric ulcer. there is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) prevention of upper gastrointestinal bleeding in critically ill patients. (5) the treatment of pathological hypersecretory conditions

OXYCODONE WOCKHARDT oxycodone hydrochloride 20 mg/2 mL solution for injection or infusion, glass ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone wockhardt oxycodone hydrochloride 20 mg/2 ml solution for injection or infusion, glass ampoules

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium citrate; water for injections; citric acid monohydrate; sodium hydroxide - oxycodone wockhardt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

OXYCODONE WOCKHARDT oxycodone hydrochloride 10 mg/1 mL solution for injection or infusion, glass ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone wockhardt oxycodone hydrochloride 10 mg/1 ml solution for injection or infusion, glass ampoules

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; citric acid monohydrate; water for injections; sodium chloride; sodium hydroxide; sodium citrate - oxycodone wockhardt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

CIMETIDINE tablet, film coated United States - English - NLM (National Library of Medicine)

cimetidine tablet, film coated

pd-rx pharmaceuticals, inc. - cimetidine (unii: 80061l1wgd) (cimetidine - unii:80061l1wgd) - cimetidine 400 mg - cimetidine tablets are indicated in: 1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see dosage and administration: duodenal ulcer). concomitant antacids should be given as needed for relief of pain. however, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years. 3. short-term treatment of active benign gastric ulcer. there is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. erosive gastroesophageal reflux (gerd). erosive esophagitis diagnosed by endoscopy. treatment is indicated for 12 weeks for

Oxycodone Juno oxycodone hydrochloride 50 mg / 1 mL solution for infusion ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 50 mg / 1 ml solution for infusion ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Oxycodone Juno oxycodone hydrochloride 200 mg / 20 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 200 mg / 20 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Oxycodone Juno oxycodone hydrochloride 20 mg / 2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 20 mg / 2 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Oxycodone Juno oxycodone hydrochloride 10 mg / 1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 10 mg / 1 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

OXYCODONE WKT oxycodone hydrochloride 20 mg/2 ml solution for injection or infusion, glass ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone wkt oxycodone hydrochloride 20 mg/2 ml solution for injection or infusion, glass ampoules

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; sodium hydroxide; water for injections; sodium chloride; sodium citrate; hydrochloric acid - oxycodone wkt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

OXYCODONE WKT oxycodone hydrochloride 10 mg/1 mL solution for injection or infusion glass ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone wkt oxycodone hydrochloride 10 mg/1 ml solution for injection or infusion glass ampoules

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate; sodium hydroxide; sodium chloride; hydrochloric acid; citric acid monohydrate - oxycodone wkt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.